What's Happening?
ACG, a global leader in solid-dosage manufacturing solutions, has announced a $200 million investment to establish its first empty-capsule manufacturing operations in the United States. The investment will
be phased, with an initial $100 million allocated to a state-of-the-art facility in Atlanta, Georgia, and a second phase of $100 million planned to expand capacity. This initiative is expected to create over 200 jobs and strengthen ACG's presence in the US market. The facilities will produce gelatin and vegetarian hard-shell capsules, adhering to high standards of quality and regulatory compliance.
Why It's Important?
ACG's investment in US manufacturing is significant for the pharmaceutical industry, as it enhances domestic production capabilities and reduces reliance on international supply chains. This move is expected to improve lead times and service quality for North American customers, while also fostering innovation through closer R&D partnerships. The creation of over 200 jobs will contribute to local economic growth and provide opportunities in the manufacturing sector. ACG's commitment to high standards and regulatory compliance ensures that the new facilities will meet the demands of the evolving pharmaceutical market.
What's Next?
Operations at the new facility in Atlanta are expected to begin in early 2027, with further expansions planned to increase capacity and capabilities. ACG will continue to integrate its US ecosystem, which includes capsules, barrier packaging materials, and encapsulation machinery, supported by nationwide sales and service teams. The company aims to leverage its global experience to deliver reliable supply and innovative solutions to North American customers. As the project progresses, ACG will likely engage with local stakeholders to ensure successful implementation and operation.
